Virpax Pharmaceuticals, Inc. · OTC:VRPX

Virpax Pharmaceuticals — IPO Roadshow (January 2021)

29 slides from Virpax Pharmaceuticals's IPO roadshow presentation, Jan 8, 2021

  1. Slide 1: Optimizing Delivery and Efficacy of Non-Addictive Pain Medicines

    OPTIMIZING DELIVERY AND EFFICACY OF NON - ADDICTIVE PAIN MEDICINES JANUARY 2021 Investor Presentation BUPIVACAINE Injectable Hydrogel for the extended release of local anesthetic DICLOFENAC Spray Film A topical anti - inflammatory for localized musculoskeletal pain ( Image is for illustration purpos

  2. Slide 2: Cautionary Note on Forward Looking Statements and Disclaimers

    CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS AND DISCLAIMERS All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, a

  3. Slide 3: Offering Summary

    Issuer Virpax Pharmaceuticals, Inc. Proposed Offering $15,000,000 Price Range $10.00 – $12.00 Proposed Symbol NASDAQ: VRPX Shares Offered 1,363,637 Pre IPO - Common Shares 3,145,153 Estimated Post IPO Common Shares 4,508,790 Use of Proceeds Advancing clinical development of Epoladerm ҹ , Probudur ҹ

  4. Slide 4: Mission Statement

    MISSION STATEMENT Our mission is to improve widely - used and newly - developed non - addictive pain medicines by optimizing their delivery systems. 4

  5. Slide 5: Trends in Pain Treatment

    “A critical part of our efforts for 2019 is new steps to promote the development of drugs to treat pain that are not addictive.” Scott Gottlieb, MD - Statement by then - FDA Commissioner on the agency’s ongoing work to forcefully address the opioid crisis, February 2019 TRENDS IN PAIN TREATMENT 5

  6. Slide 6: Investor Overview

    20% of the US Population Suffers from Chronic Pain OPIOIDS are an effective treatment option but can cause harm to patients There has been a 3X INCREASE in opioid prescriptions in the last 20 years INVESTOR OVERVIEW ▪ Developing treatments for the management of acute musculoskeletal pain, chronic pa

  7. Slide 7: Non-Addictive Analgesics Formulations in Development

    NON - ADDICTIVE ANALGESICS FORMULATIONS IN DEVELOPMENT DRUG TYPE NSAID topical spray film INDICATION Acute Musculoskeletal Pain ADDRESSABLE US MARKET $3.3 Billion Transdermal and topical non - opioid pain market (2019) CURRENT DRUG DELIVERY LIMITATIONS ▪ Low permeability of topical creams ▪ Poor pat

  8. Slide 8: Franchise Pipeline

    PRODUCT INDICATION REGULATORY PATHWAY PRE - IND MEETING PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Acute Musculoskeletal Pain Chronic Osteoarthritis (OA) Pain (OSF200) Postoperative Pain Management Acute and Chronic Pain, including Pain associated with Cancer 3 Anti - Viral Barrier 4 FRANCHISE PIPELINE

  9. Slide 9: Virpax Therapies' Drug Delivery Systems

    SKIN INCISION PRE - FILLED DEVICE WITH DICLOFENAC SOLUTION Specially formulated for metered - dosing CONCENTRATED DICLOFENAC SPRAY FILM With a high - level of adhesiveness, accessibility and skin - drying DRYING TIMES Between 60 and 90 seconds NOSE LONG - ACTING BUPIVACAINE Hydrogel encapsulated for

  10. Slide 10: A Novel, Topical Analgesic Formulation

    INDICATION REGULATORY PATHWAY PRE - IND MEETING PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Acute Musculoskeletal Pain Chronic Osteoarthritis (OA) Pain (OSF200) INDICATION MARKET SIZE DELIVERY SYSTEM Acute Musculoskeletal Pain $ 3.3 BILLION 505(b)(2) August 2018 A NOVEL, TOPICAL ANALGESIC FORMULATION 10

  11. Slide 11: Epoladerm NSAID Metered-Dose Spray Film

    EPOLADERM ҹ NSAID METERED - DOSE SPRAY FILM OVERVIEW TECHNOLOGY & IP ▪ Active drug: Diclofenac Epolamine (DHEP, diclofenac - N - (2 - hydroxyethyl) pyrrolidine) ▪ Novel topical delivery system based on proprietary spray film formulation MARKET OPPORTUNITY ▪ Treatment of acute musculoskeletal pain ▪

  12. Slide 12: The Anatomy and Action of Epoladerm Spray Film

    THE ANATOMY AND ACTION OF EPOLADERM w SPRAY FILM METERED - DOSE VALVE administers a therapeutic dose of diclofenac in an aerosolized spray CONCENTRATED DICLOFENAC SPRAY FILM with a high - level of adhesiveness, accessibility and skin - drying PRE - FILLED DEVICE WITH DICLOFENAC SOLUTION specially fo

  13. Slide 13: Epoladerm Study and Benefits

    0.00 150.00 300.00 450.00 600.00 750.00 2 4 6 8 10 12 14 16 18 20 22 24 Mean amount of diclofenac epolamine permeated through ex vivo human skin (ng) Time (h) MS77, 1.3% w/w Flector patch Epoladerm, 1.3% w/w Epoladerm w NSAID Metered - Dose Spray Film: Skin Absorption Rate Epoladerm demonstrated com

  14. Slide 14: Epoladerm Spray Film Competitive Advantages

    14 EPOLADERM ҹ SPRAY FILM Competitive Advantages SPRAY FILM versus TOPICAL PATCHES and GELS METERED - DOSE SPRAY FILM MARKET POSITION The AAFP r eleased a new clinical guideline recommending that physicians treat acute pain from non - low back musculoskeletal injuries with topical NSAIDs as first -

  15. Slide 15: Postoperative Pain Management

    INDICATION MARKET SIZE DELIVERY SYSTEM Postoperative Pain Management $ 577 MILLION LONG - ACTING LOCAL ANESTHETICS: Liposomal Encapsulated Bupivacaine INDICATION REGULATORY PATHWAY PRE - IND MEETING PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Postoperative Pain Management 505(b)(2) December 2018 15

  16. Slide 16: Probudur Long-Acting Local Anesthetic Liposomal Hydrogel

    PROBUDUR ҹ LONG - ACTING LOCAL ANESTHETIC LIPOSOMAL HYDROGEL OVERVIEW TECHNOLOGY & IP ▪ Large Multi - Vesicular Vesicle (LMVV) product delivery system, consisting of encapsulated bupivacaine in hydrogel and other “GRAS” lipids MARKET OPPORTUNITY ▪ Improved onset and longer - lasting post - operative

  17. Slide 17: Pig Wound Model: Probudur Superior to Free Bupivacaine and Exparel

    PIG WOUND MODEL: Probudur w Superior to Free Bupivacaine and Exparel ® at 96 Hours Formulation Vehicle Probudur w 30mg/kg Probudur w 50mg/kg Free Bupivacaine 9mg/kg Exparel ® 30mg/kg ▪ Probudur ҹ demonstrated longer duration and higher peak activity compared to Exparel ® ▪ Persistent analgesia noted

  18. Slide 18: Probudur vs. Free Bupivacaine and Exparel

    PROBUDUR vs. FREE BUPIVACAINE and EXPAREL® HYDROGEL ENCAPSULATION MARKET POSITION ▪ Anticipated, post - operative pain control for up to 96 hours, nearly 24 hours longer than Exparel ® ▪ Proprietary formulation for immediate and sustained pain control ▪ Developed by researchers at Hebrew University

  19. Slide 19: Enkephalin Nanoparticles with Molecular Envelope Technology

    INDICATION REGULATORY PATHWAY PRE - IND MEETING PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION Acute and Chronic Pain, including Pain associated with Cancer INDICATION MARKET SIZE DELIVERY SYSTEM Intranasal Enkephalin For Acute and Chronic Pain, including Pain associated with Cancer $ 7.0 BILLION NCE Januar

  20. Slide 20: The Novel Role of Enkephalins in Pain Management

    ▪ Enkephalins are naturally occurring analgesics in our body Enkephalins have limited therapeutic potential as they are quickly metabolized and unable to cross the blood−brain barrier (BBB) to reach their target receptors Enkephalins bind predominantly to the delta - receptor which is typically not

  21. Slide 21: Envelta Delivers Enkephalin Nanoparticles with MET

    ENVELTA ҹ DELIVERS ENKEPHALIN NANOPARTICLES WITH MOLECULAR ENVELOPE TECHNOLOGY (MET) TECHNOLOGY & IP ▪ Leucine Enkephalin (L - ENK) nanoparticles in powdered form delivered through a novel intranasal device ▪ Expiry: 11/03/34 MARKET OPPORTUNITY ▪ Potentially disrupt opioid analgesic market for the t

  22. Slide 22: Envelta Proprietary Delivery Device

    CONCEPT Single patient, multi - use device Single - use cartridges Easy activation CARTRIDGE Sealed in inert gas Pressurized Defined release ▪ No breath coordination required, simply hold the device to the nostril and press the actuator Can be self - or assisted - administration ▪ Six components to

  23. Slide 23: Envelta Competitive Advantages

    FORMULATION BENEFIT MARKET POSITION ▪ Novel enkephalin formulation ▪ Potential for comparable efficacy to mu opioid without dangerous side effects ▪ No tolerance, dependence or re ward seeking behavior in animal models ▪ MET encapsulation protects enkephalins from degradation ▪ Intranasal delivery d

  24. Slide 24: Executive Leadership

    24 Anthony P. Mack, MBA Chairman and Chief Executive Officer Gerald W. Bruce EVP, Commercial Operations EXECUTIVE LEADERSHIP • More than 25 years experience in pharmaceutical and finance industries • Founding Chairman & CEO of Virpax (led acquisition of three drug delivery platforms focused on non -

  25. Slide 25: Independent Directors

    25 Eric Floyd, PhD Chairman, Scientific and Regulatory Advice Committee Thani Jambulingam, PhD Chairman, Corporate Governance INDEPENDENT DIRECTORS • Dr. Floyd has over 21 years of regulatory experience within the pharmaceutical industry, including Axovant Sciences, Dohmen Life Science Services, Lun

  26. Slide 26: Use of Net Proceeds

    OBJECTIVE CAPITAL $7.0 Million 1.7 Million (1) (2) 1.1 Million 1.0 Million Working Capital & General and Administrative Expenses (3) 2.4 Million TOTAL $13.2 Million USE OF NET PROCEEDS (1) In August 2020, Virpax received an NCATS in - kind grant to further develop Envelta Ρ through NDA filing (2) In

  27. Slide 27: Cap Table

    CAP TABLE 3,636,310 5,056 3,145,153 486,101 27 Common Outstanding Pre - IPO Options (~$9.89 WAEP) Warrants (~$9.89 WAEP) Fully Diluted Pre - IPO *Company’s Info as of November 9, 2020

  28. Slide 28: Comparables

    COMPARABLES *Market Caps based on company’s closing share price as of January 7, 2021 $781 Million $1.77 Billion $17.57 Billion $2.94 Billion 28

  29. Slide 29: Investor Highlights

    INVESTOR HIGHLIGHTS 29 ▪ NCATS/NIH grant awarded for Envelta ҹ ▪ Envelta ҹ demonstrated effective pain control compared to morphine without analgesic tolerance ▪ Plan to file Pre - IND for Cancer Pain for Envelta ҹ in 2021 ▪ Probudur ҹ demonstrated longer duration and higher peak activity compared t

Virpax Pharmaceuticals — IPO Roadshow (January 2021) on 6ix